Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone

• Overall survival data are not yet mature, but favorable trend in OS with Intismeran plus Keytruda has been observed.

This is a clinical data readout rather than a corporate action, and the precedent for this program has been that each incremental recurrence-free survival update has carried the valuation of both partners: for Merck it defends the Keytruda franchise against its late-decade patent expiry, for Moderna it is the principal validation leg for the individualized mRNA cancer vaccine platform beyond infectious disease. The structure here follows the familiar sequence for adjuvant oncology combinations: recurrence or death benefit first, overall survival immature but trending favorable, with regulatory and commercial relevance historically hinging on whether the OS trend holds as events accumulate. Safety language of this kind, consistent with prior combination studies, is standard de-risking boilerplate for checkpoint inhibitor add-ons and has rarely been the swing factor; the swing factor has been OS maturity and durability of the recurrence signal. Points worth watching are the timing of the next data cut or conference presentation, any movement toward a filing path given that accelerated approval in this indication has precedent, and whether the OS curve converges or separates as it matures. For the partner smaller in market value, single-program readouts of this kind have historically produced outsized moves relative to the larger partner, where the reaction is typically muted by portfolio breadth.